查找临床试验
已按「白血病」检索，对应国际通用词 leukemia
共找到 12 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 09:55，每 5 分钟自动同步Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center
Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
Italy
年龄 18 Years – 75 Years
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia
Australia、Italy、Netherlands、Switzerland
年龄 不限 – 16 Years
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Spain
年龄 18 Years – 不限
PETHEMA Foundation
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
Norway
年龄 18 Years – 不限
Mendus
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
France
年龄 60 Years – 不限
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
United States
年龄 18 Years – 80 Years
Mayo Clinic
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
United States
年龄 18 Years – 不限
Rigel Pharmaceuticals
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
United States、Puerto Rico
年龄 18 Years – 不限
National Cancer Institute (NCI)
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
United States
年龄 18 Years – 不限
Northside Hospital, Inc.
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center